MedTrace Logo

Acceptability of Depo-subQ in Uniject

NCT01667276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 476

Last updated 2013-07-18

No results posted yet for this study

Summary

This is an observational study to assess the experience of current depot medroxyprogesterone acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject and offer recommendations for the introduction of this method.

Conditions

  • Contraception

Sponsors & Collaborators

  • United States Agency for International Development (USAID)

    collaborator FED

  • PATH

    collaborator OTHER

  • FHI 360

    lead OTHER

Principal Investigators

  • Holly Burke, PhD, MPH · FHI 360

  • Anthony Mbonye, MD, PhD · Ministry of Health, Uganda

  • Bpcar M Daff, MD, PhD, MSc · Division de la Sante de la Reproduction

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-03-31
Completion
2013-04-30

Countries

  • Senegal
  • Uganda

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01667276 on ClinicalTrials.gov